Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Novartis division resubmits USFDA application for biosimilar Pegfilgrastim

      Novartis division resubmits USFDA application for biosimilar Pegfilgrastim

      Farhat Nasim4 April 2019 9:15 AM IST
      New Delhi: Novartis division, Sandoz, recently announced resubmission of its Biologics License Application (BLA) for a proposed biosimilar...
      Dr Reddys arm sells US rights for Sernivo, Promises, Trianex to Encore Dermatology

      Dr Reddy's arm sells US rights for Sernivo, Promises, Trianex to Encore Dermatology

      Farhat Nasim3 April 2019 9:30 AM IST
      Dr Reddy's co-chairman and CEO G V Prasad said the announcement is in line with its renewed strategy to enable us to achieve self-sustainability and...
      USFDA issues warning letter to Rajasthan based homeopathic firm and 3 others

      USFDA issues warning letter to Rajasthan based homeopathic firm and 3 others

      Farhat Nasim3 April 2019 9:25 AM IST
      New Delhi: The U.S. Food and Drug Administration (USFDA) recently posted warning letters to four companies producing homoeopathic drug products for...
      Lupin gets EIR from USFDA for Pithampur unit

      Lupin gets EIR from USFDA for Pithampur unit

      Farhat Nasim2 April 2019 12:35 PM IST
      Lupin said its Pithampur Unit-3 facility is involved in the manufacture of metered dose inhalers (MDis), dry powder inhalers (DPis) and topical...
      Zydus Cadila gets tentative USFDA nod for Mirabegron ER tablets to treat overactive bladder

      Zydus Cadila gets tentative USFDA nod for Mirabegron ER tablets to treat overactive bladder

      Farhat Nasim2 April 2019 11:50 AM IST
      The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market generic Mirabegron extended-release...
      Cipla gets 8 USFDA observations for Kurkumbh plant

      Cipla gets 8 USFDA observations for Kurkumbh plant

      Farhat Nasim1 April 2019 9:55 AM IST
      The inspection covered three units at the plant. Post the conclusion of the inspection, the company received 8 GMP observations. The company also...
      Lupin, Aurobindo Pharma recalls multiple lots of BP drug including VALSARTAN

      Lupin, Aurobindo Pharma recalls multiple lots of BP drug including VALSARTAN

      Farhat Nasim1 April 2019 9:50 AM IST
      Aurobindo Pharma is also recalling certain lots of Amlodipine and Valsartan Tablets USP 10mg/160mg in 30 count bottles for CGMP deviations.New Delhi:...
      Jubilant Life Sciences settles IFC loan with over Rs 937 crore payout

      Jubilant Life Sciences settles IFC loan with over Rs 937 crore payout

      Farhat Nasim31 March 2019 10:15 AM IST
      Jubilant Pharma Ltd (JPL), a wholly-owned subsidiary of Jubilant Life Sciences, has redeemed a zero-coupon convertible loan with IFC based on mutual...
      HSA recalls 3 brands of high BP medicine containing LOSARTAN

      HSA recalls 3 brands of high BP medicine containing LOSARTAN

      Farhat Nasim31 March 2019 9:45 AM IST
      Singapore: Singapore's health authority on Thursday announced recall of three brands of high blood pressure medicine containing losartan, an active...
      USFDA inspected Goa facility, no observations issued: Indoco Remedies

      USFDA inspected Goa facility, no observations issued: Indoco Remedies

      Farhat Nasim30 March 2019 11:52 AM IST
      The US Food and Drug Administration (USFDA) has cleared the Goa-based sterile manufacturing facility of Indoco Remedies for finished dosages.New...
      Unichem Labs gets USFDA approval for Tadalafil Tablets

      Unichem Labs gets USFDA approval for Tadalafil Tablets

      Farhat Nasim30 March 2019 9:30 AM IST
      Tadalafil tablets are a generic version of Eli Lilly's Cialis tablets. The drug is indicated for the treatment of erectile dysfunction (ED), the signs...
      Zydus Cadila gets USFDA nod for Ambrisentan tablets to treat high BP

      Zydus Cadila gets USFDA nod for Ambrisentan tablets to treat high BP

      Farhat Nasim29 March 2019 3:17 PM IST
      Ambrisentan tablets would be manufactured at Zydus Cadila's formulations manufacturing facility at SEZ, Ahmedabad.New Delhi: Drug maker Zydus Cadila...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok